Dalotuzumab is used to inhibit tumor cell proliferation mediated by IGF-1 and IGF-2, suppress IGF-1R autophosphorylation and Akt phosphorylation, induce apoptosis, and cause cell cycle arrest; it also exhibits enhanced in vitro and in vivo antitumor activity when combined with other anticancer agents such as statins.